Genomic Health Announces Fourth Quarter and Year-End 2007 Financial Results and Business Progress and 2008 Financia...(f product revenue recorded on an accrual...),Health

Cash and cash equivalents and investments at December 31, 2007 were $68.4 million, compared to $44.2 million at December 31, 2006 and $73.9 million at September 30, 2007.

2008 Outlook and Financial Guidance

"In 2008, we will continue to seek to broaden the clinical utility of Oncotype DX by investigating ways to appropriately expand its use to help women and their physicians with treatment decisions for breast cancer, including patients with node-positive breast cancer and ductal carcinoma in situ, or DCIS," said Kim Popovits, President and Chief Operating Officer of Genomic Health. "We expect our net loss to narrow in the coming year, while we continue to invest in our product pipeline and commercial infrastructure."

The Company is providing the following financial guidance for the full year ending December 31, 2008:

* Deliver 34,000 to 37,000 test results;

* Revenue of $100 million to $110 million; and

* Net loss of $15 million to $20 million.

Recent Highlights and Accomplishments

Peer-Reviewed Publications and Medical Meeting Presentations

-- In October, ASCO included the use of Oncotype DX in updated

guidelines on the use of breast cancer tumor markers.

-- NCCN, in its 2008 Breast Cancer Treatment Guidelines, included use

of Oncotype DX to set treatment planning. Oncotype DX is the only

multi-gene expression assay to be recommended by NCCN, an alliance

of 21 world-leading cancer centers dedicated to improving the

quality and effectiveness of care provided to patients with cancer.

-- In December, eight studies were presented at the San Antonio Breast

Cancer Symposium (SABCS) reinforcing the clinical utility of

Oncotype DX. The SABCS presentations included a study presented by

the Southwe
'/>"/>